The CEPHEUS study evaluated the effectiveness of adding daratumumab to the standard VRd regimen (bortezomib, lenalidomide, and dexamethasone) in newly diagnosed multiple myeloma patients ineligible for transplant. Read more about the complete study findings and clinical implications in this Plain Language Summary of Publication article published in our partner journal Future Oncology.
Plain Language Summary
What were the results?
After 58.7 months (or approximately 5 years) from when participants started the study, more participants who received D-VRd had no signs of multiple myeloma in their bone marrow and were more likely to be alive and free from their multiple myeloma getting worse compared with participants who only received VRd. While some unwanted or undesirable effects of treatment, known as ‘side effects,’ were higher with D-VRd than VRd (such as infections), participants in both treatment groups experienced some side effects, and side effects were similar to those already known for these types of medicines.
What do the results of the study mean?
The results of the CEPHEUS study showed that among adults with a new diagnosis of multiple myeloma who could not have or did not want to have a transplant, participants who received the combination of D-VRd had better responses to treatment and lived longer free from worsening multiple myeloma compared with those who received only VRd. In addition, there were no unexpected side effects in either treatment group.
The purpose of this plain language summary is to help you to understand the findings from recent research.
Daratumumab is used to treat the disease under study that is discussed in this summary, multiple myeloma. Approvals for the use of daratumumab, either alone or in combination with other treatments, to treat multiple myeloma vary by country and region; therefore, please check with your local health care provider for more details.
The results of this study may differ from those of other studies. Health care professionals should make treatment decisions based on all available evidence, not on the results of a single study.